AT1-receptor antagonism in hypertension: what has been learned with irbesartan?

Details

Serval ID
serval:BIB_74208AC98170
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
AT1-receptor antagonism in hypertension: what has been learned with irbesartan?
Journal
Expert Review of Cardiovascular Therapy
Author(s)
Waeber B., Burnier M.
ISSN
1477-9072
Publication state
Published
Issued date
05/2003
Volume
1
Number
1
Pages
23-33
Language
english
Abstract
Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor). This compound lowers blood pressure dose-dependently in hypertensive patients and has a placebo-like tolerability. The antihypertensive efficacy of irbesartan is greatly enhanced by the coadministration of a diuretic, and fixed-dose combinations of irbesartan and hydrochlorothiazide are now available. Irbesartan-based treatment appears especially effective for high-risk patients, such as those with diabetes, renal disease and cardiac hypertrophy. In patients with Type 2 diabetes, irbesartan delays the development of nephropathy as well as the progression of renal failure. Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II. Irbesartan given alone or in combination with a diuretic therefore represents a rational approach to treat hypertensive patients.
Keywords
Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Biphenyl Compounds, Blood Pressure, Humans, Hypertension, Tetrazoles
Pubmed
Create date
25/01/2008 13:56
Last modification date
20/08/2019 15:31
Usage data